Cambium Bio (ASX:CMB) Other Long Term Assets : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Other Long Term Assets?

Cambium Bio's other long-term assets for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cambium Bio's quarterly other long-term assets declined from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then stayed the same from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.00 Mil).

Cambium Bio's annual other long-term assets increased from Jun. 2021 (A$-0.00 Mil) to Jun. 2022 (A$0.00 Mil) but then declined from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil).

Cambium Bio Other Long Term Assets Historical Data

The historical data trend for Cambium Bio's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Other Long Term Assets Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Long Term Assets

Get a 7-Day Free Trial

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															-	-	-	-	-

Cambium Bio Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines